Last reviewed · How we verify
Lipopolysaccharide
At a glance
| Generic name | Lipopolysaccharide |
|---|---|
| Also known as | there is no other intervention, Purified LPS from Escherischa coli (O:113), LPS, LPS; E. coli 0113, Endotoxin, CCRE |
| Sponsor | University of Exeter |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immune Cell Response to Stimuli
- Endotoxin Exposure to Examine the Role of Inflammation in Alcohol Use (PHASE2)
- Investigation of the Effect of Preoperative Bowel Cleansing on Postoperative Cognitive Impairment (NA)
- Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Ulcerative Colitis and Crohn Disease (NA)
- Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Thermal Burns
- Hemoperfusion Efferon LPS During Cardiac Surgery Using Cardiopulmonary Bypass (NA)
- Efferon LPS Hemoadsorption in Patients With Acute Pancreatitis (NA)
- Clearance of Antibacterial Agents During Hemoperfusion in Patients With Sepsis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipopolysaccharide CI brief — competitive landscape report
- Lipopolysaccharide updates RSS · CI watch RSS
- University of Exeter portfolio CI